Document registry — page 24
Every document the Institute has published, 1,621 in total, with its identifier, type, certainty rating and review date.
Documents
-
Observational study of Epithalon in ageing over multi-year. Primary result: The Institute has not been able to obtain a protocol, a randomisation procedure or an…
24 Feb 2025 -
Established atherosclerotic disease of the coronary, cerebral or peripheral arterial beds, or a risk profile sufficient for enrolment in a cardiovascular outcome trial.
23 Feb 2025 -
Randomised crossover, phase 1 study of Amycretin in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low23 Feb 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in type 2 diabetes randomising 731 participants over 48 weeks. Primary result: A dose-dependent…
Moderate22 Feb 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of BPC-157 in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary…
Very low22 Feb 2025 -
Phase 1 ascending dose, phase 1 study of Selank in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low18 Feb 2025 -
Domain-specific cognitive function or protection against cognitive decline, assessed by standardised neuropsychological batteries or clinical dementia rating.
15 Feb 2025 -
Does treatment with a glucagon-like peptide-1 receptor agonist increase residual gastric content at the time of elective procedural sedation?
Low13 Feb 2025 -
In the population defined for type 2 diabetes mellitus, is the effect of Mazdutide maintained across the full duration of the contributing trials?
Moderate13 Feb 2025 -
Phase 1 ascending dose, phase 1 study of Survodutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low13 Feb 2025 -
Event-driven kidney outcome trial, phase 3 study of Semaglutide in chronic kidney disease and type 2 diabetes randomising 3,533 participants over median 3.4 years…
High12 Feb 2025 -
Observational, phase 2 study of Survodutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low10 Feb 2025 -
Single-arm open-label, phase 3 study of Tirzepatide in hfpef and obesity over open-label extension of the parent trial. The Institute holds no reported primary result…
Very low08 Feb 2025 -
Long-acting amylin and calcitonin receptor agonist (acylated). Amylin is co-secreted with insulin and acts at the area postrema to promote meal-related satiation, and separately reduces gastric emptying and…
Moderate06 Feb 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low05 Feb 2025 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Exenatide compared with its comparator?
High31 Jan 2025 -
Symptomatic heart failure with a left ventricular ejection fraction of 50 % or above, occurring with obesity as a dominant phenotypic driver.
29 Jan 2025 -
Single-arm open-label, phase 3 study of Tirzepatide in sleep apnoea and obesity over open-label extension of the parent trial. The Institute holds no reported primary…
Very low29 Jan 2025 -
Synthetic tetrapeptide. Epithalon is supplied on the premise that it activates telomerase and thereby extends replicative lifespan, on the basis of cell-culture reports of…
Very low26 Jan 2025 -
What in-use period can be supported for a reconstituted research peptide solution?
Moderate23 Jan 2025 -
Randomised crossover, phase 1 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low22 Jan 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Maridebart cafraglutide compared…
Low21 Jan 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low21 Jan 2025 -
Single-arm open-label, phase 2 study of Survodutide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low20 Jan 2025 -
Steatotic liver disease with histological evidence of hepatocyte ballooning and lobular inflammation occurring in the context of at least one cardiometabolic risk…
18 Jan 2025 -
Consultation on the draft of this intervention review, which registers the question: In adults with type 2 diabetes and chronic kidney disease, what is the effect of a…
17 Jan 2025 -
Dual GIP and GLP-1 receptor agonist (acylated). Tirzepatide engages both incretin receptors from a single molecule. GLP-1 receptor agonism reproduces the insulinotropic, glucagonostatic, gastric…
High16 Jan 2025 -
Peptides, SARMs, injectable oils and raw materials. Established life-science reagent operation.
15 Jan 2025 -
Consultation on the search-strategy template used across the synthesis series: the databases searched, the structure of the strategy, the handling of registry records…
13 Jan 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of Maridebart cafraglutide in obesity randomising 592 participants over 52 weeks. Primary result: Mean change…
Low12 Jan 2025 -
In the population defined for cognitive performance and neuroprotection, what is the incidence of adverse events leading to discontinuation with Semax compared with its…
Very low11 Jan 2025 -
Consultation on the structure of the document registry: the identifier scheme, the fields carried for every document, and the way a superseded document is represented…
10 Jan 2025 -
Restoration of epithelial and dermal integrity following injury, assessed by closure rate, area reduction and scar quality.
08 Jan 2025 -
Consultation on the draft of this methodological review, which registers the question: For neuropeptides holding a national marketing registration outside the…
06 Jan 2025 -
Consultation on how the Institute should label a programme record it has constructed by grouping trials, as distinct from a programme as defined by its sponsor. The…
05 Jan 2025 -
Consultation on the draft of this safety review, which registers the question: Do incretin-based therapies increase the incidence of acute pancreatitis?
04 Jan 2025 -
Randomised, double-blind, placebo-controlled study of Semax in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low01 Jan 2025 -
Consultation on the draft monograph for Semaglutide, oral, which the assessment committee released for public comment before ratification. The draft grades the…
30 Dec 2024 -
Consultation on the draft of CEI-MS-10, which specifies the performance a determination must achieve for content and states what the resulting figure does not establish…
28 Dec 2024 -
In the population defined for cognitive performance and neuroprotection, what is the effect of Semax compared with the comparator used in its contributing trials on the…
Very low26 Dec 2024
page 24 of 41